Viktor A. Gritsenko

Viktor A. Gritsenko

Auto-generated profile, based on publicly available information

Viktor A. Gritsenko

Institute of Cellular and Intracellular Symbiosis, Orenburg Federal Research Center, Ural Branch, Russian Academy of Sciences

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
ASAnatoly Skalny
Anatoly Skalny
Michael AschnerMichael Aschner
Michael Aschner
Xin Gen LeiXin Gen Lei
Xin Gen Lei
VGViktor A. Gritsenko
Viktor A. Gritsenko
ASAbel Santamaria
Abel Santamaria
TATinkov Alexey
Tinkov Alexey
The objective of the present study was to review the existing data on the association between Zn status and characteristics of gut microbiota in various organisms and the potential role of Zn-induced microbiota in modulating systemic effects. The existing data demonstrate a tight relationship between Zn metabolism and gut microbiota as demonstrated in Zn deficiency, supplementation, and toxicity studies. Generally, Zn was found to be a significant factor for gut bacteria biodiversity. The effects of physiological and nutritional Zn doses also result in improved gut wall integrity, thus contributing to reduced translocation of bacteria and gut microbiome metabolites into the systemic circulation. In contrast, Zn overexposure induced substantial alterations in gut microbiota. In parallel with intestinal effects, systemic effects of Zn-induced gut microbiota modulation may include systemic inflammation and acute pancreatitis, autism spectrum disorder and attention deficit hyperactivity disorder, as well as fetal alcohol syndrome and obesity. In view of both Zn and gut microbiota, as well as their interaction in the regulation of the physiological functions of the host organism, addressing these targets through the use of Zn-enriched probiotics may be considered an effective strategy for health management.

31 August 2021 in Biomolecules
Verified
Journal Article
Open access
PDF file
TATinkov Alexey
Tinkov Alexey
AJAirton Cunha Martins Jr.
Airton Cunha Martins Jr.
Daiana AvilaDaiana Avila
Daiana Avila
VGVictor A. Gritsenko
Victor A. Gritsenko
ASAnatoly Skalny
Anatoly Skalny
Michael AschnerMichael Aschner
Michael Aschner
Manganese (Mn) is an essential metal, which at high exposures causes neurotoxic effects and neurodegeneration. The neurotoxic effects of Mn are mediated by neuroinflammation, oxidative and endoplasmic reticulum stress, mitochondrial dysfunction, and other mechanisms. Recent findings have demonstrated the potential impact of Mn overexposure on gut microbiota dysbiosis, which is known to contribute to neurodegeneration via secretion of neuroactive and proinflammatory metabolites. Therefore, in this review, we discuss the existing data on the impact of Mn exposure on gut microbiota biodiversity, bacterial metabolite production, and gut wall permeability regulating systemic levels. Recent data have demonstrated that Mn exposure may affect gut microbiota biodiversity by altering the abundance of Shiegella, Ruminococcus, Dorea, Fusicatenibacter, Roseburia, Parabacteroides, Bacteroidetes, Firmicutes, Ruminococcaceae, Streptococcaceae, and other bacterial phyla. A Mn-induced increase in Bacteroidetes abundance and a reduced Firmicutes/Bacteroidetes ratio may increase lipopolysaccharide levels. Moreover, in addition to increased systemic lipopolysaccharide (LPS) levels, Mn is capable of potentiating LPS neurotoxicity. Due to the high metabolic activity of intestinal microflora, Mn-induced perturbations in gut microbiota result in a significant alteration in the gut metabolome that has the potential to at least partially mediate the biological effects of Mn overexposure. At the same time, a recent study demonstrated that healthy microbiome transplantation alleviates Mn-induced neurotoxicity, which is indicative of the significant role of gut microflora in the cascade of Mn-mediated neurotoxicity. High doses of Mn may cause enterocyte toxicity and affect gut wall integrity through disruption of tight junctions. The resulting increase in gut wall permeability further promotes increased translocation of LPS and neuroactive bacterial metabolites to the systemic blood flow, ultimately gaining access to the brain and leading to neuroinflammation and neurotransmitter imbalance. Therefore, the existing data lead us to hypothesize that gut microbiota should be considered as a potential target of Mn toxicity, although more detailed studies are required to characterize the interplay between Mn exposure and the gut, as well as its role in the pathogenesis of neurodegeneration and other diseases.

27 February 2020 in Russian Journal of Infection and Immunity
Verified
Journal Article
Open access
PDF file
VZVladimir Zurochka
Vladimir Zurochka
OZO. I. Zabkov
O. I. Zabkov
MDMariya Dobrynina
Mariya Dobrynina
VGV. F. Gritsenko
V. F. Gritsenko
EDE. V. Davydova
E. V. Davydova
AZAleksandr Zurochka
Aleksandr Zurochka
Treatment of chronic viral infections accompanied by permanent virus persistence in the target epitopes of the oral cavity, skin, urogenital tract is complicated by virtual lack of available drugs exerting combined systemic virulicidal and immunomodulatory effects. Here we demonstrate clinical and immunological efficacy of combined therapy in treatment of Epstein–Barr virus (EBV)-associated chronic infections. The aim of the study was to evaluate the clinical and immunological efficacy of combined etiopathogenetic therapy using the Acegram cosmetic product in patients with EBV-associated chronic infections. Materials and methods. There were enrolled 40 patients monitored before treatment as well as 20 patients followed up after combination therapy (cycle therapy consisted of oral valaciclovir (Valtrex) applied at dose of 500 μg twice a day for 10 days, glucosaminylmuramyldipeptide (Licopid) — 10 mg 2 twice a day for 10 days, topical irrigation for mucous membranes with granulocyte-macrophage colony-stimulating factor active center-derived peptide (Acegram-spray) 3 times a day for 10 days. If necessary, treatment courses were repeated 20 days after the onset. All patients were examined for the presence of EBV genomes in the oral fluid and blood using the qualitative and quantitative polymerase chain reaction (PCR) using the DNA technology test system (Russia) on a DT-Lite device prior treatment and 30, 60 days post-therapy time points. In addition, serum samples were analyzed for level of class G immunoglobulins specific to the EBV nuclear and capsid antigens by using enzyme immunoassay (test systems manufactured by CJSC Vector Best, Russia) as well as immune status (clinical methods, enu flow cytometry evaluation of the phagocytic activity of neutrophils, ELISA method). Results. Use of single or two course combination therapy in subjects with fully eradicated EBV carriage associated with reversed clinical symptoms was accompanied by recovered immune system status (T and B cells, T-helper cells, CD3+ CD25+ cells, phagocytosis parameters). A non-invasive approach proposed for controlling virus elimination in the oral fluid by using polymerase chain reaction method may serve as to objectively monitor therapeutic efficacy.

1 January 2018 in Человек и его здоровье
Verified
Journal Article
Open access
PDF file
ПКП. П. Курлаев
П. П. Курлаев
ВГВ. А. Гриценко
В. А. Гриценко
ЮБЮ. П. Белозерцева
Ю. П. Белозерцева
Антибактериальная терапия гнойно-некротических осложнений синдрома диабетической стопы

15 April 2021 in Russian Journal of Immunology
Verified
Journal Article
Open access
PDF file
VGV. A. Gritsenko
V. A. Gritsenko
YTYa. V. Tyapaeva
Ya. V. Tyapaeva
MDM. A. Dobrynina
M. A. Dobrynina
AZAleksandr Zurochka
Aleksandr Zurochka
ТВТяпаева Я. В.
Тяпаева Я. В.
Objective of this study was to carry out comparative analysis of bactericidal activity of synthetic peptide ZP2 (SP ZP2) against museum strains and clinical isolates of Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii. Materials and methods. We used museum strains of E. coli (ATCC 25922) and P. aeruginosa ATCC 27853, as well as 104 clinical isolates of Enterobacteriaceae, including E. coli (n = 22) and K. pneumoniae (n = 82), and 98 clinical isolates of non-fermenting Gramnegative bacteria, including P. aeruginosa (n = 43) and A. baumannii (n = 55), isolated from patients with various gynecological and surgical infections. Bactericidal activity of SP ZP2 (final concentration 10 μg/ml) against the microorganisms was assessed by difference in optical density (OD) for experimental and control broth cultures after 20 min of contact of bacterial suspensions (5 x 108 CFU/ml) with SP ZP2 (in control — with distilled water), adding meat-peptone broth and 4-hour incubation at 37 °C. The effect of SP ZP2 was expressed by the Bactericidal Activity Index (BAI, %). Results. Using the in vitro assays, we have found that SP ZP2 had a pronounced bactericidal effect on both the reference strains of E. coli and P. aeruginosa, and majority (95.5-98.2%) of the studied clinical isolates of Gram-negative bacteria, regardless of their species. With regard of the average BAI values, the tested bacterial species may be ranked by increasing their sensitivity to the synthetic ZP2 peptide as follows: P. aeruginosa (74.0±2.3%) — E. coli (77.6±3.5%) — K. pneumoniae (82.8±1.6%) — A. baumannii (84.3±1.7%). In addition, significant intraspecific variability of clinical isolates of Gram-negative bacteria was revealed for their sensitivity to bactericidal effect of SP ZP2. Conclusion. The synthetic ZP2 peptide is able to inhibit growth of Gram-negative bacteria, as well as exerts a bactericidal effect, thus considering it as a promising candidate for development of new effective drugs with combined immunobiological properties for combatting infectious and inflammatory conditions caused by the indicated microorganisms which show common resistance to a wide range of antimicrobial drugs used in clinical practice.

11 August 2023 in Russian Journal of Immunology
Verified
Journal Article
Open access
PDF file
OPOlga A. Pashinina
Olga A. Pashinina
OKOlga L. Kartashova
Olga L. Kartashova
TPTatiana M. Pashkova
Tatiana M. Pashkova
VGViktor A. Gritsenko
Viktor A. Gritsenko
ПАПашинина Ольга Александровна
Пашинина Ольга Александровна
ГАГриценко Виктор Александрович
Гриценко Виктор Александрович
Our aim was to analyze the effects of the ZP2 peptide, a synthetic analogue of active center of GM-CSF, upon antilysozyme activity (ALA) of Candida. 32 vaginal isolates of Candida spp were used in the work. Five species have been isolated from the vaginal secretions of the conditionally healthy pregnant women taken within a screening program. To study the effect of ZP2 on the ALA of the Candida fungi, the fungal cells were co-cultured with a ZP2 solution in Saburo broth medium at 37 oC for 24 hours. Thereafter, ALA of fungi was determined by photometric method. It was found that the ZP2 peptide caused a decreased expression of ALA of vaginal Candida spp. Isolates, i.e., loss of ALA in the isolates of C. glabrata, C. tropicalis, C. krusei and some isolates of C. albicans, as well as a decreased level of ALA in C. kefir and other C. albicans isolates. Thus, the synthetic analogue of ZP2 peptide (active center of GM-CSF) showed an inhibitory effect upon the antilysozyme activity of Candida.